neffy
NDA- Indications
- Type I allergic reactions, Anaphylaxis
Company intelligence / Profile preview
Silverback Therapeutics
Seattle, WA, USars-pharma.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- NDA
01
Overview
Merged with ARS Pharmaceuticals in Q4/2022. Lead program SBT6050 showed limited efficacy in Phase I trials for HER2+ cancers before discontinuation.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Antibody-drug conjugates (ADCs)Immunostimulatory antibody conjugates (ISACs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Silverback Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silverback Therapeutics.